From CFGparadigms

(Difference between revisions)
Jump to: navigation, search
Line 48: Line 48:
== Acknowledgements ==
== Acknowledgements ==
The CFG is grateful to the following PIs for their contributions to this wiki page:
The CFG is grateful to the following PIs for their contributions to this wiki page: Paul Crocker, James Paulson, Ron Schnaar

Revision as of 17:57, 13 May 2010

Siglec-8 is a human siglec expressed predominantly on eosinophils and mast cells, and is a paradigm for the rapidly evolving sub-family of CD33-related siglecs that are expressed on various white blood cells[1][2][3][4]. A characteristic feature of Siglec-8 and most other CD33-related siglecs is a cytoplasmic domain with a single immunoreceptor tyrosine inhibitory motif (ITIM) and a single ITIM-like motif that participate in siglec-mediated regulation of cell signaling and endocytosis. While there is no clear ortholog in mice, Siglec-F has been documented as a functional paralog that has a similar expression pattern on murine leukocytes and similar ligand specificity[3][5][6]. Siglec-8 and its paralog Siglec-F recognize a ligand containing both sialic acid and sulfate (NeuAcα2-3[6S]Galβ1-4G[Fucα1-3]GlcNAc-), a specificity that is distinct from all other siglecs. Ligation of Siglec-8 (or Siglec-F) with antibodies or polymeric ligands induces apoptosis of eosinophils, suggesting a therapeutic approach for treating eosinophil (or mast cell) mediated disease by targeting Siglec-8[7][8][9][10].


CFG Participating Investigators contributing to the understanding of this paradigm

Participating Investigators (PIs) of the CFG have made major contributions to the understanding of the biology of Siglec-8 and its murine paralog, Siglec-F. These include: Bruce Bochner, Nicolai Bovin, Paul Crocker, James Paulson, Ronald Schnaar, Ajit Varki

Progress toward understanding this GBP paradigm

Carbohydrate ligands

NeuAcα2-3(6-SO3)Galβ1-4(Fucα1-3)GlcNAc [6'Su-SLeX]

Cellular expression

Human: Eosinophils, Mast Cells, Basophils


Biological roles of GBP-ligand interaction

Eosinophil apoptosis Inhibition of mast cell effector release

CFG resources used in investigations

The best examples of CFG contributions to this paradigm are described below, with links to specific data sets. For a complete list of CFG data and resources relating to this paradigm, see the CFG database search results for Siglec-8.

Glycan profiling

Glycan structure analysis has been conducted by the CFG for human and mouse eosinophils.

Glycogene microarray

Analysis has been conducted on glycosyltransferase expression using the glycogene microarray for murine eosinophils.

Knockout mouse lines

Glycan array

The discovery of the ligand for siglec-8 and its murine paralog, Siglec-F, was made by investigator-initiated resource requests for glycan array analysis and carbohydrate compounds.

Related GBPs

hSiglec-3 (CD33), Siglec-5, Siglec-6, Siglec, 7, Siglec-9, Siglec-10, Siglec-11, Siglec-F, Siglec-E, Siglec-G


  1. Crocker, P. R., Paulson, J. C. & Varki, A. Siglecs and their roles in the immune system. Nat Rev Immunol 7, 255-266 (2007).
  2. Kikly, K.K., Bochner, B.S., et al. Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils. J Allergy Clin Immunol 105, 1093-100 (2000)
  3. 3.0 3.1 Bochner, B.S. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin Exp Allergy 39, 317-324 (2009).
  4. Floyd, H. et al. Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily. J Biol Chem 275, 861-866 (2000).
  5. Tateno, H., Crocker, P. R. & Paulson, J. C. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology 15, 1125-1135 (2005).
  6. Zhang, M. et al. Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 109, 4280-4287 (2007).
  7. O'Reilly, M. K. & Paulson, J. C. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci 30, 240-248 (2009).
  8. Zimmermann, N. et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy 63, 1156-1163 (2008).
  9. Bochner, B. S. et al. Glycan array screening reveals a candidate ligand for Siglec-8. J Biol Chem 280, 4307- 4312 (2005).
  10. Nutku, E., Aizawa, H., Hudson, S. A. & Bochner, B. S. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 101, 5014-5020 (2003).


The CFG is grateful to the following PIs for their contributions to this wiki page: Paul Crocker, James Paulson, Ron Schnaar

Personal tools